Evaluation of the immune response induced by an oral vaccine against O26 and O111 E. coli

• Grant number: 12/11325-5
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2012
• End date: December 31, 2014
• Field of knowledge: Biological Sciences - Immunology - Applied Immunology
• Principal Investigator: Marta de Oliveira Domingos
• Grantee: Marta de Oliveira Domingos
• Host Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Roger Randal Charles New

Abstract

In Brazil, O26 and O111 E. coli are among the most isolated pathogens from children and cattle with diarrhea. These bacteria are also responsible for outbreaks of blood diarrhea and hemolytic uremic syndrome (HUS) in developed countries. Taking into consideration that 80 % of the population in Latin American has no access to drinking water or swaged, vaccination is the best way to prevent diarrhea induced by these pathogens. However, in the case of O26 and O111 E. coli, antibodies raised by the vaccine have to recognize and inhibit the adhesion of all categories of E. coli belonging to these serogroups. It has been demonstrated in our laboratory that antibodies against the O111 polysaccharide of LPS are able to recognize and inhibit the adhesion to human epithelial cells of all categories of O111 E. coli: enteropathogenic E. coli (EPEC), shiga-producing toxin E. coli (STEC) and enteroaggregative E. coli (EAEC). It has been also observed that mice orally immunized with a conjugated vaccine against the O111 antigen generated in the intestinal mucosa, IgA antibodies able to recognize different O111 E. coli strains regardless their mechanism of virulence. These data indicate that an oral conjugated vaccine that utilizes the O26 and O111 polysaccharides of the LPS as antigen targets has the potential to prevent diarrhea induced by any category of O26 and O111 E. coli. Because of the socio-economic impact of these bacteria, this project aims to develop an oral vaccine that generates in the intestinal mucosa antibodies able to recognize and inhibit the adhesion of any category of O26 and O111 E. coli. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DOMINGOS, MARTA O.; MELO, KEYDE C. M.; NEVES, IRYS VIANA; MOTA, CRISTIANE M.; RUI, RITA C.; MELO, BRUNA S.; LIMA, RAPHAEL C.; HORTON, DENISE S. P. Q.; BORGES, MONAMARIS M.; FRANZOLIN, MARCIA R.. Potential for colonization of O111:H25 atypical enteropathogenic E. coli. JOURNAL OF MICROBIOLOGY, v. 54, n. 11, p. 745-752, NOV 2016. (12/11325-5)

ANDRADE, GABRIELLE R.; NEW, ROGER R. C.; SANT'ANNA, OSVALDO A.; WILLIAMS, NEIL A.; ALVES, ROSELY C. B.; PIMENTA, DANIEL C.; VIGERELLI, HUGO; MELO, BRUNA S.; ROCHA, LETICIA B.; PIAZZA, ROXANE M. F.; et al. A universal polysaccharide conjugated vaccine against O111 E. coli. HUMAN VACCINES & IMMUNOTHERAPEUTICS, v. 10, n. 10, p. 2864-2874, OCT 2014. (13/07467-1, 12/11325-5)